Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy

Background: Immune checkpoint inhibitors (ICIs) represent a new therapeutic standard for an increasing number of tumor entities. Nevertheless, individual response and outcome to ICI is very heterogeneous, and the identification of the ideal ICI candidate has remained one of the major issues. Sarcope...

Descripción completa

Detalles Bibliográficos
Autores principales: Loosen, Sven H., van den Bosch, Vincent, Gorgulho, Joao, Schulze-Hagen, Maximilian, Kandler, Jennis, Jördens, Markus S., Tacke, Frank, Loberg, Christina, Antoch, Gerald, Brümmendorf, Tim, Neumann, Ulf P., Kuhl, Christiane, Luedde, Tom, Roderburg, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036296/
https://www.ncbi.nlm.nih.gov/pubmed/33806224
http://dx.doi.org/10.3390/jcm10071361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036296/
https://www.ncbi.nlm.nih.gov/pubmed/33806224
http://dx.doi.org/10.3390/jcm10071361

Ejemplares similares